Showing results (211-220 of 231) with videos related to
Sort By:
Pageof 24
Heart (British Cardiac Society)|October 31, 2022
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditisAntonio Brucato, Alistair Wheeler, Sushil Allen Luis, et al.European Journal of Heart Failure|October 1, 2009
Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure)Andrea Rossi, Pier Luigi Temporelli, Miguel Quintana, et al.Open Heart|January 8, 2019
Quantitative assessment of pericardial delayed hyperenhancement helps identify patients with ongoing recurrences of pericarditisArnav Kumar, Kimi Sato, Beni Rai Verma, et al.The American Journal of Cardiology|July 16, 2005
Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study)Richard W Troughton, David L Prior, Christopher M Frampton, et al.American Heart Journal|January 31, 2006
Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trialAllan L Klein, Richard A Grimm, Susan E Jasper, et al.Journal of the American College of Cardiology|April 15, 2017
Estimating Left Ventricular Filling Pressure by EchocardiographyOyvind S Andersen, Otto A Smiseth, Hisham Dokainish, et al.European Heart Journal. Imaging Methods and Practice|July 24, 2024
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditisPaul C Cremer, David Lin, Sushil A Luis, et al.European Heart Journal|September 4, 2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationRiccardo Cappato, Michael D Ezekowitz, Allan L Klein, et al.Journal of the American Heart Association|March 12, 2024
Sustained Pericarditis Recurrence Risk Reduction With Long-Term RilonaceptMassimo Imazio, Allan L Klein, Antonio Brucato, et al.American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.Pageof 24